Impact of Mitochondrial Targeting Antibiotics on Mitochondrial Function and Proliferation of Cancer Cells
Author(s) -
Edward J. Cochrane,
James Hulit,
Franz P. Lagasse,
Tanguy Lechertier,
Brett Stevenson,
Corina Tudor,
Diana Trebicka,
Tim Sparey,
Andrew J. Ratcliffe
Publication year - 2021
Publication title -
acs medicinal chemistry letters
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.065
H-Index - 66
ISSN - 1948-5875
DOI - 10.1021/acsmedchemlett.0c00632
Subject(s) - mitochondrion , doxycycline , mitochondrial ribosome , antibiotics , mitochondrial dna , ribosomal rna , cancer cell , bioenergetics , chemistry , azithromycin , biology , microbiology and biotechnology , cancer , biochemistry , ribosome , gene , genetics , rna
Some marketed antibiotics can cause mitochondria dysfunction via inhibition of the mitochondrial translation process. There is great interest in exploiting such effects within a cancer setting. To enhance accumulation of antibiotics within the mitochondria of cancer cells, and therefore delivery of a greater potency payload, a mitochondrial targeting group in the form of a triphenylphosphonium (TPP) cation was appended via an alkyl chain length consisting of 7 to 11 carbons to the ribosomal antibiotics azithromycin and doxycycline. Using MDA-MB-231 cells, the effects of each subseries on mitochondrial translation, mitochondrial bioenergetics, and cell viability are described.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom